Blood -brain barrier in health and disease

The Blood-Brain Barrier: New Research

Volumn , Issue , 2012, Pages 201-218

  Palmela, Inês ^a   Brites, Dora ^a   Brito, Maria Alexandra ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895301349     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, 2010. Structure and function of the blood-brain barrier. Neurobiol Dis. 37, 13-25.
2. Abbott NJ, Rönnbäck L, Hansson E, 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 7, 41-53.
3. Abbruscato TJ, Davis TP, 1999. Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J Pharmacol Exp Ther. 289, 668-75.
4. Ahlfors CE, Parker AE, 2010. Bilirubin binding contributes to the increase in total bilirubin concentration in newborns with jaundice. Pediatrics. 126, e639-43.
5. Akin E, Clower B, Tibbs R, Tang J, Zhang J, 2002. Bilirubin produces apoptosis in cultured bovine brain endothelial cells. Brain Res. 931, 168-75.
6. Anderson RG, 1993. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA. 90, 10909-13.
7. Andreeva AY, Krause E, Müller EC, Blasig IE, Utepbergenov DI, 2001. Protein kinase C regulates the phosphorylation and cellular localization of occludin. J Biol Chem. 276, 38480-6.
8. Babaei S, Stewart DJ, 2002. Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. Cardiovasc Res. 55, 190-200.
9. Banks WA, 2005. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des. 11, 973-84.
10. Bolton SJ, Anthony DC, Perry VH, 1998. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. 86, 1245-57.
11. Brightman MW, Reese TS, 1969. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 40, 648-77.
12. Brito MA, Lima S, Fernandes A, Falcão AS, Silva RFM, Butterfield DA, et al., 2008. Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology. 29, 259-69.
13. Brito MA, Rosa AI, Silva RFM, Falcão AS, Brites D, Oxidative stress and disruption of the nervous cell. In: CJ Resch, (Ed.), Focus on Brain Research. Nova Science Publishers, Inc., New York, 2007, pp. 1-33.
14. Brito MA, Silva RFM, Brites D, Cell response to hyperbilirubinemia: a journey along key molecular events. In: FJ Chen, (Ed.), New Trends in Brain Research. Nova Science Publishers, Inc., New York, 2006, pp. 1-38.
15. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, et al., 2000. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 6, 1362-7.
16. Cardoso FL, Brites D, Brito MA, 2010. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res Rev. 64, 328-63.
17. Carvey PM, Hendey B, Monahan AJ, 2009. The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem. 111, 291-314.
18. Cattelino A, Liebner S, Gallini R, Zanetti A, Balconi G, Corsi A, et al., 2003. The conditional inactivation of the ß-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol. 162, 1111-22.
19. Chen J, Braet F, Brodsky S, Weinstein T, Romanov V, Noiri E, et al., 2002. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol. 282, C1053-63.
20. Cirino G, Fiorucci S, Sessa WC, 2003. Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci. 24, 91-5.
21. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al., 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-ß deposition in an Alzheimer disease mouse model. J Clin Invest. 115, 3285-90.
22. Cohen RS, Wong RJ, Stevenson DK, 2010. Understanding neonatal jaundice: a perspective on causation. Pediatr Neonatol. 51, 143-8.
23. Correale J, Villa A, 2007. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity. 40, 148-60.
24. Davies DC, 2002. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 200, 639-46.
25. de Boer AG, Gaillard PJ, 2006. Blood-brain barrier dysfunction and recovery. J Neural Transm. 113, 455-62.
26. Deli MA, 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta. 1788, 892-910.
27. Dennery PA, Seidman DS, Stevenson DK, 2001a. Neonatal hyperbilirubinemia. N Engl J Med. 344, 581-90.
28. Dennery PA, Weng YH, Stevenson DK, Yang G, 2001b. The biology of bilirubin production. J Perinatol. 21 Suppl 1, S17-20.
29. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al., 2005. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-ß production. Brain Res. 1038, 208-15.
30. Dore-Duffy P, Cleary K, 2011. Morphology and properties of pericytes. Methods Mol Biol. 686, 49-68.
31. Dorheim MA, Tracey WR, Pollock JS, Grammas P, 1994. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem Biophys Res Commun. 205, 659-65.
32. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z, 2003. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 13, 259-63.
33. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, et al., 2000. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 20, 659-66.
34. Ehrlich P, 1885. Das sauerstufbudurfnis des organismus. Eine Farbenanalytische Studie, Berlin.
35. Ehrlich P, Ueber die beziehungen von chemischer constitution, vertheilung, und pharmakologischen wirkung. Collected Studies on Immunity. Wiley, Berlin, 1906, pp. 404-42.
36. Engelhardt B, 2003. Development of the blood-brain barrier. Cell Tissue Res. 314, 119-29.
37. Engelhardt B, Wolburg H, 2004. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol. 34, 2955-63.
38. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W, 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 111 (Pt 13), 1853-65.
39. Falcão AS, Fernandes A, Brito MA, Silva RFM, Brites D, 2005. Bilirubin-induced inflammatory response, glutamate release, and cell death in rat cortical astrocytes are enhanced in younger cells. Neurobiol Dis. 20, 199-206.
40. Farrell CL, Pardridge WM, 1991. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A. 88, 5779-83.
41. Fischer S, Clauss M, Wiesnet M, Renz D, Schaper W, Karliczek GF, 1999. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am J Physiol. 276, C812-20.
42. Galanakis E, Di Cello F, Paul-Satyaseela M, Kim KS, 2006. Escherichia coli K1 induces IL-8 expression in human brain microvascular endothelial cells. Eur Cytokine Netw. 17, 260-5.
43. Garcia CM, Darland DC, Massingham LJ, D'Amore PA, 2004. Endothelial cell-astrocyte interactions and TGFß are required for induction of blood-neural barrier properties. Brain Res Dev Brain Res. 152, 25-38.
44. Goldmann E, 1913. Vitalfarbung am zentralnervensystem. Abhandl Konigl preuss Akad Wiss. 1, 1-60.
45. Gordo AC, Falcão AS, Fernandes A, Brito MA, Silva RFM, Brites D, 2006. Unconjugated bilirubin activates and damages microglia. J Neurosci Res. 84, 194-201.
46. Harkness KA, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN, 2003. Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. J Neuroimmunol. 142, 1-9.
47. Harris TJ, Tepass U, 2010. Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol. 11, 502-14.
48. Hawkins BT, Davis TP, 2005. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 57, 173-85.
49. Hellström M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al., 2001. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 153, 543-53.
50. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T, 2004. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem. 89, 503-13.
51. Horwood N, Davies DC, 1994. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Arch. 425, 69-72.
52. Jian Liu K, Rosenberg GA, 2005. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med. 39, 71-80.
53. Jiang WG, Martin TA, Matsumoto K, Nakamura T, Mansel RE, 1999. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol. 181, 319-29.
54. Jodoin J, Demeule M, Fenart L, Cecchelli R, Farmer S, Linton KJ, et al., 2003. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem. 87, 1010-23.
55. Kaur C, Ling EA, 2008. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res. 5, 71-81.
56. Kliche S, Waltenberger J, 2001. VEGF receptor signaling and endothelial function. IUBMB Life. 52, 61-6.
57. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al., 2005. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 57, 176-9.
58. Kusuhara H, Sugiyama Y, 2001. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today. 6, 150-6.
59. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R, 2003. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 14, 334-47.
60. Lal BK, Varma S, Pappas PJ, Hobson RW, 2nd, Duran WN, 2001. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res. 62, 252-62.
61. Lampugnani MG, Dejana E, 2007. The control of endothelial cell functions by adherens junctions. Novartis Found Symp. 283, 4-13.
62. Lamszus K, Laterra J, Westphal M, Rosen EM, 1999. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 17, 517-30.
63. Lee CG, Tang K, Cheung YB, Wong LP, Tan C, Shen H, et al., 2004. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet. 41, e60.
64. Lee DK, Nathan Grantham R, Trachte AL, Mannion JD, Wilson CL, 2006. Activation of the canonical Wnt/ß-catenin pathway enhances monocyte adhesion to endothelial cells. Biochem Biophys Res Commun. 347, 109-16.
65. Lee TH, Avraham H, Lee SH, Avraham S, 2002. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem. 277, 10445-51.
66. Lewandowsky M, 1900. Zur lehre von der cerebrospinalflussigkeit. Z Klin Med. 40, 480-94.
67. Li Q, Zhang Q, Wang C, Liu X, Li N, Li J, 2009. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol. 218, 210-21.
68. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, et al., 2008. Wnt/ß-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 183, 409-17.
69. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, et al., 2000. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 100, 323-31.
70. Liebner S, Plate KH, 2010. Differentiation of the brain vasculature: the answer came blowing by the Wnt. J Angiogenes Res. 2, 1.
71. Lischper M, Beuck S, Thanabalasundaram G, Pieper C, Galla HJ, 2010. Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res. 1326, 114-27.
72. Man S, Ubogu EE, Ransohoff RM, 2007. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 17, 243-50.
73. Mark KS, Davis TP, 2002. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol. 282, H1485-94.
74. Michel JB, Feron O, Sacks D, Michel T, 1997. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem. 272, 15583-6.
75. Muller WA, 2011. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol. 6, 323-44.
76. Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, Nakaoke R, et al., 2007. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol. 27, 687-94.
77. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, 2006. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7, 359-71.
78. Palmela I, Cardoso FL, Bernas M, Correia L, Vaz AR, Silva RFM, Fernandes A, Kim KS, Brites D and Brito MA, 2011. Elevated levels of bilirubin and long-term exposure impair human brain microvascular endothelial cell integrity. Curr Neurovasc Res. 8, 153-169.
79. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD, 2006. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 1, 223-36.
80. Pipili-Synetos E, Sakkoula E, Maragoudakis ME, 1993. Nitric oxide is involved in the regulation of angiogenesis. Br J Pharmacol. 108, 855-7.
81. Plate KH, Breier G, Weich HA, Mennel HD, Risau W, 1994. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 59, 520-9.
82. Plumb J, McQuaid S, Mirakhur M, Kirk J, 2002. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 12, 154-69.
83. Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, Malik AB, 2005. Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol. 289, L371-81.
84. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H, 2002. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 104, 85-91.
85. Reese TS, Karnovsky MJ, 1967. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 34, 207-17.
86. Rigor RR, Hawkins BT, Miller DS, 2010. Activation of PKC isoform ßI at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab. 30, 1373-83.
87. Rite I, Machado A, Cano J, Venero JL, 2007. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem. 101, 1567-82.
88. Salkeni MA, Lynch JL, Otamis-Price T, Banks WA, 2009. Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways. J Neuroimmune Pharmacol. 4, 276-82.
89. Semenza GL, 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 19, 176-82.
90. Shapiro SM, 2010. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med. 15, 157-63.
91. Siddharthan V, Kim YV, Liu S, Kim KS, 2007. Human astrocytes/astrocyte-conditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cells. Brain Res. 1147, 39-50.
92. Song L, Ge S, Pachter JS, 2007. Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood. 109, 1515-23.
93. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV, 2006. Protein kinase Ca-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem. 281, 8379-88.
94. Steinman L, Zamvil S, 2003. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 3, 483-92.
95. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al., 2008. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 10, 923-34.
96. Tickenbrock L, Schwable J, Strey A, Sargin B, Hehn S, Baas M, et al., 2006. Wnt signaling regulates transendothelial migration of monocytes. J Leukoc Biol. 79, 1306-13.
97. Tontsch U, Bauer HC, 1991. Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res. 539, 247-53.
98. Ubogu EE, Cossoy MB, Ransohoff RM, 2006. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 27, 48-55.
99. Vadeboncoeur N, Segura M, Al-Numani D, Vanier G, Gottschalk M, 2003. Pro-inflammatory cytokine and chemokine release by human brain microvascular endothelial cells stimulated by Streptococcus suis serotype 2. FEMS Immunol Med Microbiol. 35, 49-58.
100. Vega-Diaz B, Herron GS, Michel S, 2001. An autocrine loop mediates expression of vascular endothelial growth factor in human dermal microvascular endothelial cells. J Invest Dermatol. 116, 525-30.
101. Verma S, Nakaoke R, Dohgu S, Banks WA, 2006. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun. 20, 449-55.
102. Willis CL, 2010. Glia-induced reversible disruption of blood-brain barrier integrity and neuropathological response of the neurovascular unit. Toxicol Pathol.
103. Willis CL, Meske DS, Davis TP, 2010. Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab.
104. Wispelwey B, Lesse AJ, Hansen EJ, Scheld WM, 1988. Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. J Clin Invest. 82, 1339-46.
105. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, et al., 2005. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 1053, 10-8.
106. Yuan SY, 2002. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol. 39, 213-23.
107. Zhang W, Smith C, Shapiro A, Monette R, Hutchison J, Stanimirovic D, 1999. Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro. J Neuroimmunol. 101, 148-60.
108. Zlokovic BV, 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57, 178-201.